Novartis’ Xolair recommended under new global chronic urticaria guidelines

Novartis has announced that its drug Xolair has been recommended for use as a treatment for chronic spontaneous urticaria (CSU) in newly-published global guidelines.

The guidance has endorsed Xolair as an add-on therapy for the treatment of chronic spontaneous urticaria among patients who are not responding to antihistamines. It is the only licensed treatment option for CSU among this patient group.

To date, Xolair has been the only treatment option to be qualified with very good efficacy and safety in CSU, thus paving the way for key dermatologic and allergy professional medical societies around the world to recommend the drug under this new guidance.

Studies have shown that poorly-controlled CSU can have a major impact on the quality of sleep and the social and working lives of patients. Xolair has been shown to offer significant quality of life benefits, as well as sustainable symptom control.

Dr Shreeram Aradhye, chief medical officer and global head of medical affairs at Novartis Pharmaceuticals, said: "The recommendation reinforces the important role of Xolair to provide effective symptom control in CSU when antihistamines prove inadequate. Xolair is the only biologic shown to be effective in CSU."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.